Search Results - "van Moorselaar, J"

Optimization and validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer by Luining, Wietske I., Oprea-Lager, Daniela E., Vis, André N., van Moorselaar, Reindert J. A., Knol, Remco J. J., Wondergem, Maurits, Boellaard, Ronald, Cysouw, Matthijs C. F.

“…IntroductionRadiomics extracted from prostate-specific membrane antigen (PSMA)-PET modeled with machine learning (ML) may be used for prediction of disease…”
Get full text

A protocol for urine collection and storage prior to DNA methylation analysis by Bosschieter, J, Bach, S, Bijnsdorp, I V, Segerink, L I, Rurup, W F, van Splunter, A P, Bahce, I, Novianti, P W, Kazemier, G, van Moorselaar, R J A, Steenbergen, R D M, Nieuwenhuijzen, J A

“…Urine poses an attractive non-invasive means for obtaining liquid biopsies for oncological diagnostics. Especially molecular analysis on urinary DNA is a rapid…”
Get full text

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial by Janssen, J, Staal, F H E, Brouwer, C L, Langendijk, J A, de Jong, I J, van Moorselaar, R J A, Schuit, E, Verzijlbergen, J F, Smeenk, R J, Aluwini, S

“…More than 60% of oligo-recurrent prostate cancer (PCa) patients treated with metastasis-directed radiotherapy (MDRT) develop biochemical recurrence within…”
Get full text

The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population by Westgeest, H. M., Kuppen, M. C. P., van den Eertwegh, A. J. M., de Wit, R., Bergman, A. M., van Moorselaar, R. J. A., Coenen, J. L. L. M., van den Bergh, A. C. M., Somford, D. M., Mehra, N., van Oort, I. M., Aben, K. K. H., Gerritsen, W. R., Uyl-de Groot, C. A.

“…Background In 2004 docetaxel was the first life-prolonging drug (LPD) registered for metastatic castration-resistant prostate cancer (mCRPC) patients. Between…”
Get full text

Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer by Oprea-Lager, Daniela E, Vincent, Andrew D, van Moorselaar, Reindert J A, Gerritsen, Winald R, van den Eertwegh, Alfons J M, Eriksson, Jonas, Boellaard, Ronald, Hoekstra, Otto S

“…To investigate whether time-trends of enhanced [(18)F]Fluoromethylcholine ([(18)F]FCH) in lymph nodes (LN) of prostate cancer (PCa) patients can help to…”
Get full text

Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer by Cysouw, Matthijs C. F., Jansen, Bernard H. E., van de Brug, Tim, Oprea-Lager, Daniela E., Pfaehler, Elisabeth, de Vries, Bart M., van Moorselaar, Reindert J. A., Hoekstra, Otto S., Vis, André N., Boellaard, Ronald

“…Purpose Quantitative prostate-specific membrane antigen (PSMA) PET analysis may provide for non-invasive and objective risk stratification of primary prostate…”
Get full text

Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project by Postema, A. W., De Reijke, T. M., Ukimura, O., Van den Bos, W., Azzouzi, A. R., Barret, E., Baumunk, D., Blana, A., Bossi, A., Brausi, M., Coleman, J. A., Crouzet, S., Dominguez-Escrig, J., Eggener, S., Ganzer, R., Ghai, S., Gill, I. S., Gupta, R. T., Henkel, T. O., Hohenfellner, M., Jones, J. S., Kahmann, F., Kastner, C., Köhrmann, K. U., Kovacs, G., Miano, R., van Moorselaar, R. J., Mottet, N., Osorio, L., Pieters, B. R., Polascik, T. J., Rastinehad, A. R., Salomon, G., Sanchez-Salas, R., Schostak, M., Sentker, L., Tay, K. J., Varkarakis, I. M., Villers, A., Walz, J., De la Rosette, J. J.

“…Purpose To reach standardized terminology in focal therapy (FT) for prostate cancer (PCa). Methods A four-stage modified Delphi consensus project was…”
Get full text

Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer by Wondergem, M., Jansen, B. H. E., van der Zant, F. M., van der Sluis, T. M., Knol, R. J. J., van Kalmthout, L. W. M., Hoekstra, O. S., van Moorselaar, R. J. A., Oprea-Lager, D. E., Vis, A. N.

“…Purpose Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using…”
Get full text

Simplified Methods for Quantification of 18F-DCFPyL Uptake in Patients with Prostate Cancer by Jansen, Bernard HE, Yaqub, Maqsood, Voortman, Jens, Cysouw, Matthijs CF, Windhorst, Albert D, Schuit, Robert C, Kramer, Gerbrand M, van den Eertwegh, Alfons JM, Schwarte, Lothar A, Hendrikse, N Harry, Vis, André N, van Moorselaar, Reindert JA, Hoekstra, Otto S, Boellaard, Ronald, Oprea-Lager, Daniela E

“…Radiolabeled prostate-specific membrane antigen (PSMA) PET has demonstrated promising results for prostate cancer (PCa) imaging. Quantification of PSMA…”
Get full text

Renal cancer and pneumothorax risk in Birt–Hogg–Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families by Houweling, A C, Gijezen, L M, Jonker, M A, van Doorn, M B A, Oldenburg, R A, van Spaendonck-Zwarts, K Y, Leter, E M, van Os, T A, van Grieken, N C T, Jaspars, E H, de Jong, M M, Bongers, E M H F, Johannesma, P C, Postmus, P E, van Moorselaar, R J A, van Waesberghe, J-Htm, Starink, T M, van Steensel, M A M, Gille, J J P, Menko, F H

“…Background: Birt–Hogg–Dubé (BHD) syndrome is an autosomal dominant condition caused by germline FLCN mutations, and characterised by fibrofolliculomas,…”
Get full text

Renal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow-up by Widdershoven, Christiaan V., Aarts, Brigitte M., Zondervan, Patricia J., Henderickx, Michaël M. E. L., Klompenhouwer, Elisabeth G., van Delden, Otto M., Prevoo, Warner, Montauban van Swijndregt, Alexander D., van Moorselaar, Reindert J. A., Bex, Axel, Lagerveld, Brunolf W.

“…Purpose To assess the difference between renal mass biopsy (RMB) performed either before or during the ablation procedure. Methods A retrospective multicenter…”
Get full text

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry by van den Bergh, Gijs P. A., Kuppen, Malou C. P., Westgeest, Hans M., Mehra, Niven, Gerritsen, Winald R., Aben, Katja K. H., van Oort, Inge M., van Moorselaar, Reindert J. A., Somford, Diederik M., van den Eertwegh, Alfonsus J. M., Bergman, André M., van den Bergh, Alphonsus C. M., Uyl-de Groot, Carin A.

“…Background The objective of this real-world population study is to investigate incidence and treatment of visceral metastases (VMs) in castration resistant…”
Get full text

Patient reported outcome measures concerning urinary incontinence after robot assisted radical prostatectomy: development and validation of an online prediction model using clinical parameters, lower urinary tract symptoms and surgical experience by Collette, Eelco R. P., Klaver, Sjoerd O., Lissenberg-Witte, Birgit I., van den Ouden, Dies, van Moorselaar, Reindert J. A., Vis, André N.

“…The prediction of post-prostatectomy incontinence (PPI) after robot-assisted radical prostatectomy (RARP) depends on multiple clinical, anatomical and surgical…”
Get full text

Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer by Jansen, Bernard HE, Cysouw, Matthijs CF, Vis, André N, van Moorselaar, Reindert JA, Voortman, Jens, Bodar, Yves JL, Schober, Patrick R, Hendrikse, N Harry, Hoekstra, Otto S, Boellaard, Ronald, Oprea-Lager, DE

“…Quantitative evaluation of radiolabeled prostate-specific membrane antigen (PSMA) PET scans may be used to monitor treatment response in patients with prostate…”
Get full text

Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial by Jansen, B. H. E., Bodar, Y. J. L., Zwezerijnen, G. J. C., Meijer, D., van der Voorn, J. P., Nieuwenhuijzen, J. A., Wondergem, M., Roeleveld, T. A., Boellaard, R., Hoekstra, O. S., van Moorselaar, R. J. A., Oprea-Lager, D. E., Vis, A. N.

“…Purpose The detection of lymph-node metastases (N1) with conventional imaging such as magnetic resonance imaging (MRI) and computed tomography (CT) is…”
Get full text

New experimental markers for early detection of high-risk prostate cancer : role of cell-cell adhesion and cell migration by MOL, A. J. M, GELDOF, A. A, MEIJER, G. A, VAN DER POEL, H. G, VAN MOORSELAAR, R. J. A

“…Today's treatment and diagnosis of prostate cancer still exhibit major limitations. The search for new and additional prognostic markers is therefore still an…”
Get full text

Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone by Jansen, Bernard HE, Kramer, Gem M, Cysouw, Matthijs CF, Yaqub, Maqsood M, Keizer, Bart de, Lavalaye, Jules, Booij, Jan, Vargas, Hebert Alberto, Morris, Michael J, Vis, André N, van Moorselaar, Reindert JA, Hoekstra, Otto S, Boellaard, Ronald, Oprea-Lager, Daniela E

“…PET is increasingly used for prostate cancer (PCa) diagnostics. Important PCa radiotracers include 68Ga-prostate-specific membrane antigen HBED-CC (68Ga-PSMA),…”
Get full text

Letter to the Editor re: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake by Cysouw, M. C. F., Jansen, B. H. E., Yaqub, M., Voortman, J., Vis, A. N., van Moorselaar, R. J. A., Hoekstra, O. S., Boellaard, R., Oprea-Lager, D. E.

Get full text

Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial by Bodar, Y. J. L., Jansen, B. H. E., van der Voorn, J. P., Zwezerijnen, G. J. C., Meijer, D., Nieuwenhuijzen, J. A., Boellaard, R., Hendrikse, N. H., Hoekstra, O. S., van Moorselaar, R. J. A., Oprea-Lager, D. E., Vis, A. N.

“…Purpose In primary prostate cancer (PCa) patients, accurate staging and histologic grading are crucial to guide treatment decisions. 18 F-DCFPyL (PSMA)-PET/CT…”
Get full text

Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer by Jansen, Bernard HE, Jansen, Robin W, Wondergem, Maurits, Srbljin, Sandra, de Klerk, John MH, Lissenberg-Witte, Birgit I, Vis, André N, van Moorselaar, Reindert JA, Boellaard, Ronald, Hoekstra, Otto S, Oprea-Lager, Daniela E

“…Biochemically recurrent prostate cancer (BCR) is the main indication to perform prostate-specific membrane antigen PET/CT. However, localizing BCR with…”
Get full text